title: Elevation of soluble CD23 in serum from patients with blood eosinophilia.
abstract: The levels of soluble CD23 (sCD23) were evaluated by a two-site immunoradiometric assay in the sera of 41 patients with eosinophilia-associated disorders and 20 normal subjects. We observed that, in the absence of treatment, sCD23 levels were elevated in patients with eosinophilia-associated Gleich's syndrome, IgA deficiency, T lymphoma or hypereosinophilic syndrome (HES), but not in patients with a parasitic infection. A significant reduction in the sCD23 levels was found after treatment, with a parallel decrease in eosinophil counts and in sCD25 levels, a marker of disease activity in HES. The lack of increase in membrane CD23+ B cells in eosinophilic patients together with the detection of sCD23 in eosinophil supernatants suggest that activated eosinophils present in eosinophilia-associated disorders can release soluble molecules cross-reacting with CD23. In conclusion, our results suggest that eosinophils themselves can represent one cellular source of sCD23. These findings are not only basic but also of clinical interest.
authors.affiliation: Centre d'Immunologie et de Biologie Parasitaire, Unité Mixte INSERM U167-CNRS 624, Institut Pasteur, Lille, France.
authors.forename: D
authors.initials: D
authors.lastname: Aldebert
authors.forename: L
authors.initials: L
authors.lastname: Prin
authors.forename: J P
authors.initials: JP
authors.lastname: Dessaint
authors.forename: D
authors.initials: D
authors.lastname: De Groote
authors.forename: A
authors.initials: A
authors.lastname: Capron
authors.forename: M
authors.initials: M
authors.lastname: Capron
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000954:Antigens, Surface / Q000032:analysis; D001402:B-Lymphocytes / Q000276:immunology; D004802:Eosinophilia / Q000097:blood* / Q000188:drug therapy; D004804:Eosinophils / Q000276:immunology; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D017098:IgA Deficiency / Q000097:blood / Q000276:immunology; D016898:Interferon-alpha / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010272:Parasitic Diseases / Q000097:blood / Q000276:immunology; D017455:Receptors, IgE / Q000032:analysis*; D015375:Receptors, Interleukin-2 / Q000032:analysis; D012995:Solubility
chemical_list: D000305:Adrenal Cortex Hormones; D000954:Antigens, Surface; D016898:Interferon-alpha; D017455:Receptors, IgE; D015375:Receptors, Interleukin-2